Is argenx SE (ARGX) a Buy, Sell, or Hold?
argenx SE
NASDAQ:ARGX
$859.43 USD
-$16.82 (-1.92%)
- Volume
- 269.86K
- Average Volume
- 343K
- Market Capitalization
- $53.77B
- P/E Ratio
- 48.78
- Dividend Yield
- 0.00%
- Price Target
- $1157.50
- Year High
- $953.58
- Year Low
- $554.59
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.23
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Timothy Van Hauwermeiren |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ARGX |
| CUSIP | 04016X101 |
| CIK | 0001697862 |
| Web | https://www.argenx.com |
| Phone | 31 10 703 8441 |
| Currency | USD |
| Employees | 1863 |
| Country | NL |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.23 |
| Quick Ratio | 4.87 |
| Cash Ratio | 2.64 |
Sales & Book Value
| Annual Sales | $4.15B |
| Price / Sales | 16.03 |
| Cash Flow | 12.09 |
| Price / Cash Flow | 72.90 |
| Price / Book | 7.30 |
Price Target and Rating
| Average Stock Price Forecast | $1157.50 |
| High Stock Price Forecast | $1291.00 |
| Low Stock Price Forecast | $940.00 |
| Forecast Upside/Downside | -25.75% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 36 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $19.63 |
| Trailing P/E Ratio | 48.78 |
| PEG Ratio | 0.07 |
| P/E Growth | 0.07 |
| Net Income | $1.29B |
| Net Margin | 33.42% |
| Pretax Margin | 32.03% |
| Return on Equity | 16.82% |
| Return on Assets | 13.00% |
Financials Score
| AltmanZ Score | 23.03 |
| Piotroski Score | 5.00 |
| Working Capital | 5.58B |
| Total Assets | 8.68B |
| Ebit | 1.27B |
| Market Cap | 47.81B |
| Total Liabilities | 1.36B |
Poll Results
About argenx SE (NASDAQ:ARGX) Stock
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejectio ... n. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.
Are Medical Stocks Lagging Argenx (ARGX) This Year?
2026-07-13 10:40:31
Here is how argenex SE (ARGX) and Cardinal Health (CAH) have performed compared to their sector so far this year.
FTRE or ARGX: Which Is the Better Value Stock Right Now?
2026-07-07 12:41:12
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
This Profitable Autoimmune Biotech Trades Near A High And A Buy Point
2026-07-06 13:10:18
This profitable Netherlands-based biotech name has produced triple-digit quarterly earnings growth.
Live Nasdaq Composite: Markets Kick Off H2 2026 on Cautious Note amid Chip Stock Profit Taking
2026-07-01 09:42:56
Live Updates Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now. Wells Fargo's Q3 Outlook 51 minutes ago Live Wells Fargo is betting on a strong summer for stocks, telling clients the Q3 sets up nicely for a rally before midterm election... Live Nasdaq Composite: Markets Kick Off H2 2026 on Cautious Note amid Chip Stock Profit Taking
Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study
2026-06-25 13:57:56
Argenx SE (NASDAQ:ARGX) stock has faced pressure after the company disclosed changes to the analysis plan for its ongoing Phase 3 Vyvgart study in myositis.
Can Argenx Retake Its Record High — And A Buy Point — On A New Vyvgart Strategy?
2026-06-24 10:29:19
Argenx stock reversed course Wednesday, bumping above its 21-day line, as investors digested its myositis-focused R&D Day.
2026-06-24 01:32:09
argenx SE (ARGX) Discusses R&D Spotlight on Advancing FcRn Leadership in Autoimmune Myositis Transcript
argenx Eyes More VYVGART Growth as Pipeline Catalysts Near
2026-06-12 07:07:03
Executives at argenex NASDAQ: ARGX told investors at a Goldman Sachs healthcare event that they continue to see meaningful growth opportunities for VYVGART across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, while also pointing to a busy slate of pipeline readouts in the second half of the year.
Frequently Asked Questions
-
What is the current argenx SE (ARGX) stock price?
-
argenx SE(NASDAQ:ARGX) stock price is $859.43 in the last trading session. During the trading session, ARGX stock reached the peak price of $953.58 while $554.59 was the lowest point it dropped to. The percentage change in ARGX stock occurred in the recent session was --1.92% while the dollar amount for the price change in ARGX stock was -$-16.82.
-
ARGX's industry and sector of operation?
-
The NASDAQ listed ARGX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ARGX?
-
Timothy Van Hauwermeiren EMBA | Co-Founder & Non-Independent Non-Executive Chairman of the Board
Karen Massey | Chief Executive Officer & Executive Director
Hans de Haard Ir | Co-Founder & Member of Board Advisors
Filip Borgions | Chief Technology Innovation Officer
Achim Plueckebaum | Global Head of Digital Technologies -
How many employees does ARGX have?
-
Number of ARGX employees currently stands at 1863. ARGX operates from Laarderhoogtweg 25, Amsterdam, NH 1101EB, NL.
-
Link for ARGX official website?
-
Official Website of ARGX is: https://www.argenx.com
-
How do I contact ARGX?
-
ARGX could be contacted at phone #31 10 703 8441 and can also be accessed through its website. ARGX operates from Laarderhoogtweg 25, Amsterdam, NH 1101EB, NL.
-
How many shares of ARGX are traded daily?
-
The average number of ARGX shares traded daily for last 3 months was 343K.
-
What is the market cap of ARGX currently?
-
The market value of ARGX currently stands at $53.77B with its latest stock price at $859.43